Abstract
We have developed quantitative methods which enable us to measure susceptibility to sensitization with dinitrochlorobenzene (DNBC) and the degree of responsiveness of groups, and to analyse factors affecting the afferent and efferent components of the response. Five groups of normal subjects (132 individuals) were sensitized with DNCB (1,000, 500, 250, 125 or 62.5 micrograms). One month later, each subject was challenged with 12.5, 6.25 and 3.125 micrograms of DNCB on standard patch test felts. After 48 h the reaction at each challenge site was graded clinically and measured as diameter of induration and increase in skinfold thickness. The proportion of subjects sensitized increased with sensitizing dose; 8% were sensitized by 62.5 and 100% were sensitized by 500 micrograms or more. The 50% sensitizing dose (ED50) was calculated as 116 micrograms. Increase in skinfold thickness proved the best method of assessing response and was linearly related to log challenge dose. There was also a linear relationship between degree of sensitivity and log sensitizing dose so that, on average, each time sensitizing dose was halved, the challenge dose required to produce the same response increased 1.5-fold. These methods can be used to measure sensitizability of a population, the degree of sensitivity and the expression of reactivity. The technique will allow quantitative study of factors altering the induction or expression of such reactivity in disease.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bleumink E., Nater J. P., Schraffordt Koops H., The T. H. A standrard method for DNCB sensitization testing in patients with neoplasms. Cancer. 1974 Apr;33(4):911–915. doi: 10.1002/1097-0142(197404)33:4<911::aid-cncr2820330404>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
- Cook J., Shuster S. Histamine weal formation and absorption in man. Br J Pharmacol. 1980 Aug;69(4):579–585. doi: 10.1111/j.1476-5381.1980.tb07907.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- EPSTEIN W. L., MAIBACH H. I. IMMUNOLOGIC COMPETENCE OF PATIENTS WITH PSORIASIS RECEIVING CYTOTOXIC DRUG THERAPY. Arch Dermatol. 1965 Jun;91:599–606. doi: 10.1001/archderm.1965.01600120031006. [DOI] [PubMed] [Google Scholar]
- Eilber F. R., Morton D. L. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970 Feb;25(2):362–367. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
- Lowney E. D. Attenuation of contact sensitization in man. J Invest Dermatol. 1968 Mar;50(3):244–249. [PubMed] [Google Scholar]
- Watson M. A., Briggs J. D., Diamandopoulos A. A., Hamilton D. N., Dick H. M. Endogenous cell-mediated immunity, blood transfusion, and outcome of renal transplantation. Lancet. 1979 Dec 22;2(8156-8157):1323–1326. doi: 10.1016/s0140-6736(79)92812-5. [DOI] [PubMed] [Google Scholar]